Adriblastina 20 Ready To Use 20 mg Injektionslösung Bélgica - alemão - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 20 ready to use 20 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 20 mg - doxorubicin-hydrochlorid 20 mg - doxorubicin

Adriblastina 200 Ready To Use 200 mg Injektionslösung Bélgica - alemão - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 200 ready to use 200 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 200 mg - doxorubicin-hydrochlorid 200 mg - doxorubicin

Adriblastina 50 Ready To Use 50 mg Injektionslösung Bélgica - alemão - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

adriblastina 50 ready to use 50 mg injektionslösung

pfizer - doxorubicin-hydrochlorid - injektionslösung - 50 mg - doxorubicin-hydrochlorid 50 mg - doxorubicin

Celdoxome pegylated liposomal União Europeia - alemão - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxorubicinhydrochlorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastische mittel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Adriblastin 50 mg Trockenstechampulle Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

adriblastin 50 mg trockenstechampulle

pfizer corporation austria gmbh - doxorubicin hydrochlorid - doxorubicin

Adriblastin 200 mg Stechampulle Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

adriblastin 200 mg stechampulle

pfizer corporation austria gmbh - doxorubicin hydrochlorid - doxorubicin

Adriblastin 50 mg Stechampulle Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

adriblastin 50 mg stechampulle

pfizer corporation austria gmbh - doxorubicin hydrochlorid - doxorubicin

Adriblastin 10 mg Stechampulle Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

adriblastin 10 mg stechampulle

pfizer corporation austria gmbh - doxorubicin hydrochlorid - doxorubicin

Ribodoxo 2 mg/ml Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ribodoxo 2 mg/ml

hikma farmaceutica (portugal), s.a. (8007071) - doxorubicinhydrochlorid - injektionslösung - doxorubicinhydrochlorid (06460) 10 milligramm

Adrimedac 2 mg/ml Infusionslösung Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

adrimedac 2 mg/ml infusionslösung

medac gesellschaft für klinische spezialpräparate m.b.h. (3083854) - doxorubicinhydrochlorid - infusionslösung - teil 1 - infusionslösung; doxorubicinhydrochlorid (06460) 2 milligramm